fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-07-19 Novasep (France)
instrAction (Germany)

chromatography processes for purification
other
See details
2010-07-19 Vivalis (France)

Boehringer Ingelheim (Germany)
EB66® cell line for production of two poultry vaccines
licensing
See details
2010-07-16 Galapagos (Belgium)
University of Bristol (UK)
new analgesic drug based on the protein galanin, small protein that has been shown to reduce neuropathic pain in a number of models of diseases, including diabetes.
/ Diabetic neuropathic pain
R&D
development
See details
2010-07-15 Cytos Biotechnology (Switzerland)
Singapore’s Agency for Science, Technology and Research (A*STAR)

virus-like particle (VLP) vaccine
/ influenza
R&D
commercialization/ distribution
development
See details
2010-07-15 Lonza (Switzerland)
Elusys Therapeutics (USA)

Anthim®
This humanized and deimmunized monoclonal antibody targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins.
/ Anthrax
manufacturing
See details
2010-07-13 Human Genome Sciences (USA)
Lonza (Switzerland)

Benlysta® (belimumab - BLyS-specific inhibitor) It is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.
/ stemic lupus erythematosus
manufacturing
See details
2010-07-12 OctoPlus (The Netherlands)
The Medicines Company (USA)
MDCO-216 (ApoA-I Milano/phospholipid complex).
manufacturing
development
See details
2010-07-12 Galapagos (Belgium)
NIH (USA)

Molecular Libraries Small Molecule Repository (MLSMR) other
See details
2010-07-08 Eurofins MWG Operon (Germany)
Genomatix (Germany)
Sequencing solutions
other
See details
2010-07-07 Proximagen (UK)
National Institute of Neurological Disorders and Stroke (NINDS – USA)
Naluzotan (5-HT1a receptor agonist)
Proximagen is currently undertaking studies in models of Parkinson’s disease to determine the utility of naluzotan in alleviating dyskinesia induced by dopaminergic therapy. / epilepsy
other
See details
2010-07-07 TcLand Expression (France)
Inserm Transfert (France - technology transfer subsidiary of the French National Institute for Health and Medical Research - Inserm)
Patents covering gene expression signatures which can predict responsiveness to rheumatoid arthritis.
The first patent application WO2007IB02373, has been filed on May 15, 2007 and is entitled “A method for predicting responsiveness to TNF alpha blocking agents” (first-listed inventor: Jean-Philippe Salier).
The second one, EP 083052522, has been filed on June 12, 2008 and is entitled “A method for predicting the response to a treatment with anakinra” (first-listed inventor: Thierry Lequerré).
/ rheumatoid arthritis
licensing
See details
2010-07-07 Aquapharm Biodiscovery (UK)
Albany Molecular Research (USA)
Composé drug-like compounds with anti-microbial and anti-inflammatory activity / inflammatory diseases, infectious diseases R&D
See details
2010-07-06 Pharming (the Netherlands)

Sanofi Chimie (France)
Ruconest® (Rhucin® - recombinant human complement protein C1 inhibitor (rhC1INH), produced in transgenic rabbit milk) / angioedema attacks manufacturing
See details
2010-07-06 Swedish Orphan Biovitrum (Sweden)
Dongbao (China)
  commercialization/ distribution
See details
2010-07-05 MRC Technology (UK)

AstraZeneca (UK)
compound libraries / serious diseases including the area of cancer, cardiovascular diseases, neuroscience, and infection R&D
See details
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]